Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Major Depressive Disorder (MDD), Depression - Major Depressive Disorder
In brief
This study aimed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) in patients with major depressive disorder (MDD) who exhibit suboptimal early response to antidepressant treatment. Additionally, it sought to investigate the impact of FMT on biological indicators, including intestinal microbiota and metabolites, in individuals with MDD
Key facts
- Study ID
- NCT06692361
- Run by
- Gang Wang
- People needed
- 214
- Starts
- 2025-01-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2025-12-02
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The First Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China (enrolling)
- Beijing Anding Hospital — Beijing, Beijing Municipality, China (enrolling)
- Wuhu Fourth People's Hospital — Wuhu, Anhui, China (enrolling)
- The First Affiliated Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (enrolling)
- Shandong Daizhuang Hospital — Jining, Shandong, China (enrolling)
- West China Hospital Affiliated of Sichuan University — Chengdu, Sichuan, China (enrolling)
- Tianjin Anding Hospital — Tianjin, Tianjin Municipality, China (enrolling)
- The Second People's Hospital of Dali Bai Autonomous Prefecture — Dali, Yunnan, China (enrolling)
- Nangfang Hospital Affiliated of Southern Medical University — Guangzhou, Guangdong, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.